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Objective of review :  
Surgical site infections are a recognised complication of cochlear implant (CI) surgery 
with significant morbidity. Our aim was to search for the optimum prevention and 
management strategy to deal with this issue. 
 
Type of review : Systematic review 
 
Search strategy : 
A systematic literature search was undertaken from the databases of EMBASE, CINAHL, 
MEDLINE®, Web of Science, Scopus and Cochrane Library according to predefined 
inclusion and exclusion criteria. 
 
Evaluation method : All relevant titles, abstracts and full text articles were reviewed 
by two authors who resolved any differences by discussion and consultation with senior 
authors. 
 
Results :  
14 articles were included in our review. The overall quality of evidence was low with 
the vast majority of the studies being retrospective case series and expert opinions. No 
randomised-controlled trials were noted. We found consistent reports that intra-
operative prophylactic antibiotics should be given to all patients undergoing CI and that 
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Conclusion : 
Our review has not identified any reliable or reproducible strategies to prevent and deal 
with wound infections after CI. We strongly encourage further research within this field 
and would suggest that a consensus of opinions from a multidisciplinary panel of 
experts may be a pragmatic way forward as an effective guide.  
 





 Surgical site infections are a recognised complication of cochlear implantation 
 Incidence rates vary in the literature from 1 - 13% 
 Our systematic review identified 14 articles that focused on strategies on 
preventing and managing a wound infection after cochlear implantation 
 The overall quality of evidence was low with most studies being retrospective 
case series and no level 1 evidence available. 
 Due to the difficulties in developing prospective and randomised-controlled 
studies within the field, we propose a multidisciplinary consensus opinion 





The introduction and expansion of cochlear implantation (CI) technology has 
revolutionised the management of profound hearing loss worldwide 1. Despite being 
a relatively straightforward operation, complications can be disastrous with 
infection contributing to significant morbidity 2. 
 
These operations are generally classified as clean-contaminated due to the risk of 
pathogenic translocation through the eustachian tube 3. Post-operative infections 
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delayed) of infection. Minor infections are cases of simple wound inflammation 
where conservative outpatient management would suffice and major is when the 
patient requires hospitalisation, requires further surgery, develops central nervous 
system complications or requires explanation of the device4. Early infections occur 
within the first 4 weeks after implantation and delayed infections occur after. The 
overall incidence seems to vary throughout the literature with differences seen in 
adult and paediatric population, however general figures range between 1 - 13% 5,6. 
 
With the burden of soft tissue infections well documented to both patient and 
health-care institutions, we were motivated to investigate the best practice 
management to prevent and deal with such a complication. Our aim was to review 
the literature in the hope of findings strategies that would reduce the need for major 
treatment or explantation. It would be very useful to distinguish between wound 
infections and those arising perhaps from contamination of the receiver-stimulator 
package, but due to a lack of a standardised definition or distinction in the papers 
(and indeed in practice it can sometimes be very difficult to tell), we incorporated all 
infection and inflammation pertaining to the surgical site and surrounding soft 


































This review was undertaken in line with PRISMA-P 2015 guidelines 7. A literature 
search was performed on the engines EMBASE, CINAHL, MEDLINE®, Web of 
Science, Scopus and Cochrane Library using the following medical subject headings 
(MeSH) and free text words in varying combinations; cochlear implants, cochlear 
implantation, auditory implant, auditory prosthesis, Advance Bionics, Cochlear, Oticon, 
Med-El, wound healing, wound infection, prosthesis-related infections, postoperative 
complications, bandages, wound heal, wound infect, wound management, wound care, 
wound complications, wound swell, wound clean, wound dressings, wound stitch, 
wound suture, wound bandage, anti-infective agents, antibiotic prophylaxis, penicillins, 
cephalosporins, aminoglycosides, quinolones, clindamycin, metronidazole, 
trimethoprim, mupirocin, pseudomonic acid, neomycin, fusidic acid, framycetin, 
polymyxins, chlortetracycline, antisepsis, soaps, iodophors, povidone, iodine, betadine, 
disinfectant, eusol, dakin, benzalkonium, chlorhexidine, alcohols,  hydrogen peroxide, 
benzoyl peroxide, gentian violet, hypochlorous acid, hexachlorophene, potassium 
permanganate, silver, silver sulfadiazine, honey (Appendix 1) 
 
1. Systematic review protocol and data extraction 
The initial 15566 results were narrowed down to 9267 titles after duplicates were 
removed. Two authors (AV and DB) independently screened through the titles and 
selected 44 abstracts that focused on wound infections after CI. The same two 
authors subsequently screened the abstracts independently who then reviewed 32 
full papers to assess eligibility. All disagreements were resolved by discussion 
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The excluded papers included case reports, conference proceedings, papers that 
focused solely on incidence reporting and non-related wound infections. Two full-
text articles were unavailable to source and hence were excluded.  Studies 
containing duplicated data from previously published work were also excluded, as 
were review articles, editorials and letters. No restrictions were placed on study 
design or study population. (Figure 1) 
 
All titles, abstracts, full text articles and referencing were handled using Mendeley 
Desktop v1.17 2008-2017. Our selection process is outlined in our PRISMA diagram 
in Figure 1. 
 
2. Data analysis  
Due to the variety of outcome measures employed by different authors, statistical 
meta-analysis of results was not possible. Results were therefore presented 
descriptively.  
 
3. Risk of bias and quality assessment  
All studies were assessed for quality and risk of bias by both reviewers, according to 
a modification of the system described in the Cochrane Handbook for Systematic 
Reviews of Interventions version 5.1.0.18 8. Because of the large number of 
retrospective, non-randomized, non-blinded studies, more weight was placed on 
description of the preventative and treatment methods.  
 
4. Ethical consideration 
As the manuscript took the form of a review without the use of patient data or 
details, ethical review and registration with the local research department was 
































14 full text articles were reviewed looking at evidence-based approach to the 
prevention and management of wound infections after CI surgery. A summary of the 
papers and their findings can be found in Table 1. We had broken down the analyses 
to multiple factors under two main headings; prevention and management.  
 
A. Prevention of wound infections 
1. Pre-operative factors 
There were two published papers, by Clark and Gluth, stating their expert opinion 
on potentially modifiable factors prior to CI surgery. Clark et al. subjectively felt that 
swabbing all patients and staff involved in the surgery to identify pathogen like 
Staphylococcal species (spp.) pre-operatively so that they could be treated in 
adequate time.9 Suggestions were also made to remove staff from the operating 
theatre environment if their repeat swabs were still positive. The authors found 
waxing the patients' hair, having their ears cleaned and skin scrubbed with 0.5% 
chlorhexidine in 70% alcohol a few days before surgery beneficial for their overall 
infection risk.9 
 
Gluth et al. stated that patient comorbidity was an important risk factor in 
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studies with chronic otitis media and recommended that active pathology should 
first be dealt with before implantation can be considered. This involved surgical 
approaches of tympanoplasties, mastoid obliterations or blind sac closure and a 
staged approach after the ear has been rendered disease-free 2. Both of the 
aforementioned studies did not provide any hard data to show a reduction in 
infection rate from the proposed measures.   
 
Low et al.’s retrospective case series found that the only 2 adult CI infections out of 7 
in their series of 432 adult and paediatric patients had prior radiotherapy for head 
and neck tumours and felt that this was a strong contributing factor, due to the 
impairment in wound healing 10. 
 
2. Antibiotics 
i) Type of antibiotics 
Hirsch's retrospective case series of 95 patients undergoing CI found that cefazolin 
was the commonest (83% of cases) pre-operative prophylactic antibiotic used. They 
reported no major infections and just one minor one of an inflamed incision line in 
the early post-operative period (within the first month) 11. This choice of antibiotic 
was echoed by Almosnino's 2018 series with clindamycin / vancomycin 
combination used in patients with penicillin allergy 12. Other studies have reported 
using cefuroxime and co-amoxiclav 3. The authors felt these antibiotics would cover 
the common microorganisms that would migrate from skin or middle ear mucosa 
and cause an infection.  
 
ii) Time given 
Hirsch et al. and Almosnino et al. had the prophylactic antibiotics given 30 minutes 
before skin incision. Both retrospective non-comparative studies reported no major 
infections. 11,12  
iii) Duration 
Garcia-Valdecasas et al. reported a cohort study on 192 patients who had a 
combination of ceramic-coated CI (eg. MED-EL implants) and titanium-silicon coated 
CI (eg. Cochlear Nucleus and Advanced Bionics implants). The authors looked at 4 
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who received 6 weeks of clarithromycin post-op in addition to a pre-operative dose 
of ceftriaxone had significantly lower chances of infections compared to their 
counterparts who only had the pre-operative ceftriaxone dose (relative risk 
reduction of 8:1).  They hypothesized that the presence of biofilms on these specific 
implant surfaces played a prime role and that clarithromycin had a bacteriostatic 
and bacteriocidal properties at low and high doses respectively.  Recommended 
dosing regimen was 125 mg/24 hours in children under 4 years old; 250 mg/ 24 
hours in children more than 4 years, and 500 mg/24 hours in adults. Interestingly, 
the study reported 9 infections, all of which occurred in patients with titanium-
silicon coated CI and all of which required explantation despite aggressive 
intravenous antibiotics and surgical washouts 13.  
 
On the contrary, Basavaraj et al.'s retrospective case series showed that the rate of 
infection in the early post-operative period was higher in patients who had 
prolonged prophylactic antibiotics, with infection rates being 5.6% in 5-day regimen 
and 13% in 7-day regimen 3. Alongside this, Almosnino reported no difference in 
infection rates between 2 groups of patients with and without prolonged pre-
operative prophylactic antibiotics despite having more diabetics in the group that 
received only a single shot.12 
3. Skin prep 
Both iodine-based preparations 12 and 0.5% chlorehexidine in 70% alcohol 9 have 
been reported, although no direct comparisons were made between the two.  
 
4. Incision 
There have been recommendations for incisions to be made over a drape to reduce 
the chance of skin flora migration into the wound 9,12.  Smaller incisions no more 
than 4cm were cited as the ideal size 2,12 with infection rates reported to be higher in 
patients who had c-shaped incisions (11.1%) 5 and extended endaural incisions 
(7.5%).  A post-aural approach has been cited to reduce the risk of complications by 
15-fold 14. Gawecki et al. compared long c-shaped and short post-aural incisions 
when they changed their practice in 2007 and found that although their rates of 
major skin flap complications halved from 2.43% (11 of 452) to 1.28% (8 out of 
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rates of infection 5. Davids et al. reported similar results where the rates of soft 
tissue complications were roughly 1% with a smaller incision 6,15. 
 
5. Device preparation 
A few papers (non-comparative retrospective series and expert opinion) proposed 
soaking the electrodes in antibiotic solutions of vancomycin 12 and ampicillin / 
cloxacillin 9 as well as bathing the mastoid cavity and round window niche with the 
respective solutions prior to opening the round window membrane.  
 
6. Device placement 
Gluth et al. subjectively suggested that the receiver-stimulator package should be 
placed well away from the incision line and not in contact with patients' spectacles 
to prevent pressure necrosis.2 Davids et al. felt that device fixation was an important 
aspect of paediatric cochlear implantation due to the thinner soft tissue envelope 
protecting the receiver-stimulator package and relatively more minor head trauma 
incidences compared to adult patients 16.   
 
7. Closure and sutures 
Both Almosnino et al. and Gluth et al. were advocates of multi-layered closure with a 
tight periosteum layer 2,12. Clark et al. felt that monofilaments sutures should be 
used to close the deeper wounds, as they were less likely to form a reservoir for 
infection compared to braided sutures 9. Low et al., on the other hand, found that 
monofilament polyprolene skin sutures were the culprit for 4 out of 5 stitch abscess 
in paediatric CI patients 10. Cryanoacrylate adhesives were proposed as a method for 
skin closure 12. 
 
8. Dressings / wound protection 
Almosnino's protocol of mastoid dressings for 24 hours followed by a shower on the 
first post-operative day did not have any significant impact on rates of wound 
healing, infection or skin reaction although there were no comparative data 
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B. Management of wound infections 
1. Types of bacteria 
Staphylococcal spp. and Pseudomonas spp. were the commonly identified bacteria in 
the vast majority of studies 1,5,6,10,14,17,18. Recognised subtypes of Staphylococcal spp. 
include aureus as well as methicillin-resistant and susceptible epidermidis strains 17.  
Davids et al. had reported that 2 patients in their series of 452 recipients of CI who 
had suffered trauma and migration of their magnets went on to grow Haemophilus 
influenzae in their swabs 6.  
 
Biofilm production on package complexes has been suggested as one of the main 
contributing factors in delayed and recurrent wound infections.1,17 Olsen et al. had 
visually assessed their infected implants during surgical treatment for biofilms and 
sent swabs away for microbiological culture and sensitivities. They noted that 8 out 
of 11 infected implants had biofilm growths of which 7 were ultimately explanted. 5 
of these implants cultivated Staphylococcal aureus 1.  In Palau et al.'s series, scanning 
electron microscopes were used to examine the 3 explanted CIs, where 2 were noted 
to have Staphylococcal aureus and epidermidis biolfilms on them 17. 
 
Pseudomonas aeruginosa infections were felt to be more sinister and resulted in 
explantation in 2 out of the 4 serious wound infections in Kabelka et al.'s 
retrospective series 14. In agreement with other published data, the authors felt that 
Pseudomonal spp. infections tend to manifest as gradual soft tissue swellings which 
ultimately results in a 'pseudocapsule' around the implant, denuding the blood 
supply and hence rendering systemic antimicrobial therapy ineffective.  This 
commonly results in a fistula with surrounding granulation tissue and serous 
secretions. As such, they recommended that these implants would serve better being 




Various different antibiotic regimens have been used based on local microbiological 
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In Kabelka et al.'s series, they had used a combination of ceftazidime and tazocin for 
16 days alongside frequent irrigation with polymixin, neomycin and hydrogen 
peroxide for one of their infected CI, which unfortunately required explantation 
after 5 weeks. Another case, which grew Pseudomonas spp., had 21 days of 
ceftriaxone and ciprofloxacin combination therapy followed by 4 weeks of oral 
ciprofloxacin before being explanted. They successfully saved two implants, which 
required drainage of pus and intravenous co-amoxiclav for Staphloccocal aureus 
growth 14. 
 
Davids et al. had 2 cases which grew Staphloccocal aureus that were successfully 
treated with cefazolin (duration not stated) 6. The 2 cases that grew Haemophilus 
influenzae after trauma initially settled with intravenous Tazocin, however recurred 
6 months later requiring explantation. 
 
Olsen et al. had generally treated postoperative infections with beta-lactamase 
inhibitor antibiotics (eg. Dicillin). This was provided microbiological swabs had not 
displayed resistance or grown an organism sensitive to another microbial agent. In 
severe cases, intravenous cephalosporins were used in combination with 
metronidazole 1. 
 
Palau et al. reported 7 cases of wound infection without device exposure of which 4 
cases were successfully treated with oral co-amoxiclav, with swabs growing 
Staphlococcal aureus and methicillin sensitive Staphylococcal epidermidis. 2 patients 
with methicillin-resistant Staphylococcal epidermidis, on the other hand, were 
successfully treated with oral levofloxacin 17.   
 
Although many of the studies had not stated their duration of treatment, Low et al. 
subjectively felt that a prolonged intravenous administration of at least 6 weeks 
should be attempted alongside direct topical antibiotics to the device through 
washouts and irrigation tubes 10.  
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Low et al. were able to salvage their 8 infected CI with a combination of washouts 
and antibiotics. They performed local debridement of the infected wound and a 
thorough washout of the device with chlorhexidine and erythromycin. They had 
occasionally transposed the device to a different pocket if the overlying skin did not 
appear healthy. Post-operatively, a butterfly needle was left in place to allow daily 
antibiotics irrigation (based on culture and sensitivities or erythromycin if no 
growth) for 5 days 10. 
 
In Olsen et al.'s series, they had ensured pus swabs were sent for culture and 
sensitivities and had used Genta-coll®, a resorbable collagen sponge containing 
gentamicin, around the implant. They hypothesized that this would help deliver a 
high concentration of antibiotic substance directly onto the implant, which would 
help against biofilms. This modality saved 3 out of the 7 wound infections that 
underwent surgical therapy 1.  
 
ii) Flaps and Repositioning 
In an expert consensus document, Rubin and Papsin emphasized that adequate 
covering of a CI device was vital in reducing the need for explantation. They referred 
to two separate series' where 8 out of 9 patients with device exposure eventually 
underwent explantation in comparison to 3 out of 17 wound infections without 
device exposure 18.  
 
Gawecki et al. strongly advocate a rotational two-flap technique to cover an infected 
CI alongside intensive targeted antibiotic therapy can be effective and should be first 
line of treatment. They had employed this philosophy for the delayed major skin flap 
complications that presented after 1 month and up to 10 years post-implantation. 
The two layers were described as skin with a subcutaneous layer and muscle with 
fascia and had been successful in 3 out of 4 of their wound infections.  
 
Rubinstein described four cases were the pedestal of the CI had become exposed 
through skin infections and were subsequent moved to a healthier site and covered 
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iii) Explantation 
This is ultimately the treatment for patients who have had unsuccessful primary 




















Summary of main results 
Our systematic review of the 14 articles found a general lack in high-level evidence 
on ways of preventing and managing wound infections in CI (Table 1). The vast 
majority of studies were level 4 retrospective case series based on the Oxford Centre 
for Evidence-based Medicine grading 20. The highest quality of evidence was a 
cohort study by Garcia-Valdecasas et al. 13 conducted in Spain and published in the 
Laryngoscope in 2009. The lack of randomised-controlled trials and systematic 
reviews precluded us from conducting a meta-analyses.  
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We divided the articles into those focusing on prevention and management of CI 
wound infections and had 5 and 8 articles in each category respectively (Table 1). 
Gluth et al.'s expert opinion article published in Cochlear Implants International in 
20112 was included in both categories, although we also found information on 
prevention in some of the studies grouped under the management heading. 
 
In the prevention category, Garcia-Valdecases et al.'s comparative cohort study 
provided some insight into the how wound infections can differ in varying implants 
due to their surface coating. The comparisons between ceramic and titanium-
silicone implants were marred by their unequal numbers in all four arms (21 and 24 
patients in ceramic arm vs 76 and 75 in the titanium-silicon arm), however, the 
authors strongly suggest that patients with titanium-silicone (eg. implants (Cochlear 
Nucleus and Advanced Bionics) do have fewer wound infections when covered with 
6 weeks of post-operative clarithromycin (relative risk 8.1) 13. The findings may play 
a role in helping patients decide between their choice of implant type and brand as 
well as guide clinicians in their consent process for wound infection risks and post-
operative management. Interestingly, very few centres cover patients with a long 
course of post-operative antibiotics, as seen in our review, and none have reported a 
wound infection rate as high as Garcia-Valdecases et al.'s 10.67% 13. We were unable 
to find explanations to account for the outlier number of infections in this series nor 
the reason the infections only occurred on titanium-silicone implants despite fairly 
equal baseline characteristics across all four subgroups.  One may postulate if there 
could have been issues with implant batch or sterility over the study period that 
predisposed to biofilm formation or wound infection' 
 
The choice, duration and regimen of prophylactic antibiotics remain a contention in 
the literature, although there seems to be a general agreement that all CI patients 
should receive them due to its role within the early post-operative period (first 30 
days) 11. The lack of comparative studies in Hirsch et al. and Basavaraj et al. series 
make it difficult to form a consensus opinion especially as their findings of 
prolonged prophylactic antibiotics show increased infection rates in contradiction to 
Garcia-Valdecases et al.'s results 3,11,13.  The concordance of antibiotic type used by 
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general cephalosporin, may be a suitable prophylaxis agent for Staphylococcal 
spp..11,12,21 However, its lack of action against Pseudomonas spp21, which is also 
commonly found in wound infections with a high rate of explantation 14, would 
suggest that well-conducted comparative trials should be done to investigate newer 
and broader-spectrum agents against both gram positive and negative 
microorganisms. (eg. Tazocin, Gentamicin, Co-Amoxiclav).  
 
Another consistent recommendation within the literature was the use of smaller 
post-aural incisions 2,5,12,14, however the evidence supporting this was generally 
weak. One comparative study by Gawecki et al. showed that although the rates of 
skin flap complications had halved with smaller incisions, this was statistically 
insignificant. It is difficult to power studies with enough numbers in each arm for 
very low incidences of occurrence, such as infections.  It is now common practice 
that smaller incisions are employed to minimise flap failures and breakdown, 
however a correlation with wound infection has not been studied. Despite the lack 
of evidence, common sense would dictate that a smaller incision would provide a 
lesser raw surface area for microorganisms to grow in, reducing surgical site 
infection 22,23 while also minimising post-operative pain morbidity.  The 
recommendations for skin prep, device preparation and placement, method of 
wound closure and post-operative dressings were generally based on single centre 




Implications for clinical practice 
Reviewing the studies that focused on the management of CI wound infections, we 
found fairly consistent reports that the vast majority of infections were caused by 
Staphyloccocal spp. and Pseudomonas spp. Pseudomonal spp. appeared to be the more 
sinister with a 100% explantation rate, although this was only from 2 patients 14. 
Two studies had reported their experience with biofilm formation on the implant 
surfaces 1,17 which would certainly account for the relapsing infections also seen in 
our experience.  The concept of biofilms on implant surfaces is certainly emerging 
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Despite the relative certainty in causal microorganisms, the intended therapy 
seemed to vary amongst the different studies. The evidence behind type and 
duration of antibiotics as well as nature of surgical treatment was inconsistent and 
insubstantial mainly due to the overall small numbers and lack of comparisons in 
treatment methodologies (Table 1). There was, however, a trend of effectiveness of 
penicillin-based and cephalosporin antibiotics against Staphyloccoccal spp.  
 
The management of wound infections with device exposure requires a more 
aggressive treatment strategy due to the higher risk of explantation26. The mostly 
opinion-based reports we had found suggest that these implants should be treated 
with antibiotics and surgically covered with flap transposition5 or moved to a safer 
location19 in an attempt to salvage the package. The latter can be difficult to achieve 
without accidental removal of the electrodes from the cochlear and ought to be 
performed with threshold monitoring on table. Our own practice, based on 
accumulated personal experience is that such measures can be fruitful in dry 
implant exposures, however not in discharging wounds where we find the failure to 
eradicate infection rate is higher and explanation would be a better first-line option 
to hasten recovery, although we do not have rigorous data to fully support this. 
 
The lack of separated data makes it difficult to compare prevention and 
management strategies between adults and children. Most studies 4,13,5 have found 
the incidence of wound infections to be similar across both subgroups, and generally 
espouse similar management strategies, although there are some suggestions that 
device fixation16 may be more pertinent in children who are liable to the implant 
package slipping due to their anatomy and daily activities. Low et al.4 found that 
stitch abscess was the commonest contributing factor in children mostly from 
monofilament polyprolene sutures used, although similar risks could easily be 
postulated to exist amongst adults. 
 
We were also unable to find a clear and consistent methodology across most of the 
papers (except Hirsch et al.)11 on how the diagnoses of wound infections were made 
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robustness could well have bearings on the suitability and efficacy of management 
strategy employed especially if they were to be replicated for patients with post-
implantation complications. 
 
Implications for research 
Looking forward, we feel that the paucity in evidence represents a void in this 
important aspect of post-operative CI care. We appreciate that conducting large 
scale randomised-controlled or comparative trials may not be a feasible way to 
answer the questions we set out to discover in this review. A more pragmatic 
alternative may be a consensus opinion from a multidisciplinary panel of experts 
comprising of surgeons, audiologists and microbiologists through a Delphi process 
to streamline pre-operative management and post-operative treatment strategies. 
Additionally, the creation of a national database of implants, similar to the National 
Joint Registries 27, would amass a large collection of data that could yield pertinent 
information on how such infections are treated at various implant centres across the 
country with the aim of reducing unwanted variation based on successful 
techniques. We also appreciate that implantation in ENT is a relatively new and 
growing field and can draw lessons from specialties such as orthopaedics that have 
acquired an abundance of experience and research data on infection prevention and 
management with implants. Lastly, we suggest that future laboratory endeavours 
should focus on identifying biofilm formation on the varying implant surfaces to 
identify prevention strategies as well as to guide clinicians and patients in their 








The evidence behind prevention and management techniques for CI-related wound 
infections is lacking. Because of this, we are unable to form a consensus or 
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and strategies to reduce explantation rates. Further research in this area is highly 
desirable, perhaps through multi-centre data and randomised trials, especially as 
these infections present a substantial morbidity to the patient while incurring large 
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Appendix 1. Search strategy 
 
Medline 
1. Cochlear Implants/ or Cochlear Implantation/   
2. (auditory adj5 (implant* or prosthe*)).mp 
3. (Advance bionics or Cochlea* or Oticon or Med-El).mp 
4. 1 or 2 or 3 
5. Wound Healing/ or exp Wound Infection/ or Prosthesis-Related Infections/ or exp postoperative 
complications/ or exp Bandages/ 
6. (wound* adj5 (heal* or infect* or management or care or complication* or swell* or clean* or dressing* or 
stitch* or suture* or bandage*)).mp 
7. (exp Anti-Infective Agents/ or Antibiotic Prophylaxis/ or exp Penicillins/ or exp 
Cephalosporins/ or exp Aminoglycosides/ or exp Quinolones/ or exp Clindamycin/ or 
exp Metronidazole/ or exp Trimethoprim/ or exp Mupirocin/ or exp Neomycin/ or exp 
Fusidic Acid/ or exp Framycetin/ or exp Polymyxins/ or exp Chlortetracycline/) 
8. (antibiotic* or antimicrobial* or antibacterial* or penicillin* or cephalosporin* or aminoglycoside* or 
quinolone* or clindamycin or metronidazole or trimethoprim or mupirocin or pseudomonic acid or 
neomycin or fusidic acid or framycetin or polymyxin* or chlortetracycline) 
9. (exp antisepsis/ or exp Soaps/ or exp Iodophors/ or exp Chlorhexidine/ or exp 
Alcohols/ or exp Hydrogen Peroxide/ or exp Benzoyl Peroxide/ or exp Gentian Violet/ 
or exp Hypochlorous Acid/ or exp Hexachlorophene/ or exp Potassium 
Permanganate/ or exp Silver/ or exp Silver Sulfadiazine/ or exp Honey/ 
10. (antiseptic* or soap* or iodophor* or povidone or iodine or chlorhexidine or betadine 
or alcohol* or disinfectant* or hydrogen peroxide or benzoyl peroxide or gentian violet 
or hypochlorit* or eusol or dakin* or hexachlorophene or benzalkonium or potassium 
permanganate or silver or silver sulphadiazine or honey*) 
11. 5 or 6 or 7 or 8 or 9 or 10 
12. 4 and 11 
Embase 
1. exp cochlea prosthesis/ or cochlear implantation/ 
2. (auditory adj5 (implant* or prosthe*)) 
3. (Advance bionics or Cochlea* or Oticon or Med-El) 
4. 1 or 2 or 3 
5. exp wound healing/ or wound infection/ or infection/ or exp postoperative complication/ or exp bandage/ 
6. (wound* adj5 (heal* or infect* or management or care or complication* or swell* or clean* or dressing* or 
stitch* or suture* or bandage*)) 
7. exp antiinfective agent/ or exp penicillin derivative/ or exp cephalosporin derivative/ or exp 
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trimethoprim/ or exp pseudomonic acid/ or exp neomycin/ or exp fusidic acid/ or exp framycetin/ or exp 
polymyxin/ or exp chlortetracycline/ 
8. (antibiotic* or antimicrobial* or antibacterial* or penicillin* or cephalosporin* or 
aminoglycoside* or quinolone* or clindamycin or metronidazole or trimethoprim or 
mupirocin or pseudomonic acid or neomycin or fusidic acid or framycetin or 
polymyxin* or chlortetracycline) 
9. exp antisepsis/ or Soaps/ or exp iodophor/ or exp chlorhexidine/ or exp alcohol derivative/ or exp 
hydrogen peroxide/ or exp benzoyl peroxide/ or exp crystal violet/ or exp hypochlorous acid/ or exp 
hexachlorophene/ or exp permanganate potassium/ or exp silver/ or exp sulfadiazine silver/ or exp 
honey/ 
10. (antiseptic* or soap* or iodophor* or povidone or iodine or chlorhexidine or betadine 
or alcohol* or disinfectant* or hydrogen peroxide or benzoyl peroxide or gentian violet 
or hypochlorit* or eusol or dakin* or hexachlorophene or benzalkonium or potassium 
permanganate or silver or silver sulphadiazine or honey*) 
11. 5 or 6 or 7 or 8 or 9 or 10 
12. 4 and 11 
 
Cinahl 
1. (MH "Cochlear Implant") 
2. (auditory adj5 (implant* or prosthe*)) 
3. ("Advance bionics" or Cochlea* or Oticon or Med-El) 
4. S1 OR S2 OR S3 
5. (MH "Wound Healing") or (MH "Wound Infection+") or (MH "Prosthesis-Related Infections") or 
(MH "Postoperative Complications") or (MH "Bandages and Dressings+") 
6. (wound* N5 (heal* or infect* or management or care or complication* or swell* or clean* or 
dressing* or stitch* or suture* or bandage*)) 
7. (MH "Chlorthalidone") or (MH "Polymyxins+") or (MH "Fusidic Acid") or (MH "Neomycin") or 
(MH "Mupirocin") or (MH "Trimethoprim+") or (MH "Metronidazole") or (MH "Clindamycin") or 
(MH "Antiinfective Agents, Quinolone+") or (MH "Aminoglycosides+") or (MH 
"Cephalosporins+") or (MH "Penicillins+") or (MH "Antiinfective Agents+") 
8. (antibiotic* or antimicrobial* or antibacterial* or penicillin* or cephalosporin* or 
aminoglycoside* or quinolone* or clindamycin or metronidazole or trimethoprim or 
mupirocin or pseudomonic acid or neomycin or fusidic acid or framycetin or 
polymyxin* or chlortetracycline) 
9. (MH "Honey") or (MH "Silver Sulfadiazine") or (MH "Silver") or (MH "Hexachlorophene") or 
(MH "Hypochlorous Acid+") or (MH "Gentian Violet") or (MH "Peroxides+") or (MH "Hydrogen 
Peroxide") or (MH "Alcohols+") or (MH "Chlorhexidine") or (MH "Iodophors+") or (MH 
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10. (antiseptic* or soap* or iodophor* or povidone or iodine or chlorhexidine or betadine or 
alcohol* or disinfectant* or hydrogen peroxide or benzoyl peroxide or gentian violet or 
hypochlorit* or eusol or dakin* or hexachlorophene or benzalkonium or potassium 
permanganate or silver sulfadiazine or silver sulphadiazine or honey*) 
11. S5 OR S6 OR S7 OR S8 OR S9 OR S10 
12. S4 AND S11 
 
Web of Science 
1. (auditory NEAR/5 (implant* or prosthe*)) 
2. ("Advance bionics" or Cochlea* or Oticon or Med-El) 
3. #2 OR #1 
4. (wound* NEAR/5 (heal* or infect* or management or care or complication* or swell* or 
clean* or dressing* or stitch* or suture* or bandage*)) 
5. ((antibiotic* or antimicrobial* or antibacterial* or penicillin* or cephalosporin* or 
aminoglycoside* or quinolone* or clindamycin or metronidazole or trimethoprim or 
mupirocin or "pseudomonic acid" or neomycin or "fusidic acid" or framycetin or 
polymyxin* or chlortetracycline)) 
6. ((antiseptic* or soap* or iodophor* or povidone or iodine or chlorhexidine or betadine 
or alcohol* or disinfectant* or "hydrogen peroxide" or "benzoyl peroxide" or "gentian 
violet" or hypochlorit* or eusol or dakin* or hexachlorophene or benzalkonium or 
"potassium permanganate" or silver or "silver sulphadiazine" or honey*)) 
7. #6 OR #5 OR #4 
8. #7 AND #3 
 
Scopus 
1. TITLE-ABS-KEY ( ( auditory  W/5  ( implant*  OR  prosthe* ) ) )  
2. TITLE-ABS-KEY ( ( "Advance bionics"  OR  cochlea*  OR  oticon  OR  med-el ) )  
3. ( TITLE-ABS-KEY ( ( auditory  W/5  ( implant*  OR  prosthe* ) ) ) )  OR  ( TITLE-ABS-
KEY ( ( "Advance bionics"  OR  cochlea*  OR  oticon  OR  med-el ) ) )  
4. TITLE-ABS-
KEY ( ( wound*  W/5  ( heal*  OR  infect*  OR  management  OR  care  OR  complication*  
OR  swell*  OR  clean*  OR  dressing*  OR  stitch*  OR  suture*  OR  bandage* ) ) )  
5. ( TITLE-ABS-
KEY ( antibiotic*  OR  antimicrobial*  OR  antibacterial*  OR  penicillin*  OR  cephalospori
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hoprim  OR  mupirocin  OR  "pseudomonic acid"  OR  neomycin  OR  "fusidic 
acid"  OR  framycetin )  OR  TITLE-ABS-KEY ( polymyxin*  OR  chlortetracycline ) ) 
6. ( TITLE-ABS-
KEY ( antiseptic*  OR  soap*  OR  iodophor*  OR  povidone  OR  iodine  OR  chlorhexidine 
 OR  betadine  OR  alcohol*  OR  disinfectant*  OR  "hydrogen peroxide"  OR  "benzoyl 
peroxide"  OR  "gentian violet"  OR  hypochlorit* )  OR  TITLE-ABS-
KEY ( eusol  OR  dakin*  OR  hexachlorophene  OR  benzalkonium  OR  "potassium 
permanganate"  OR  silver  OR  "silver sulphadiazine"  OR  honey* ) )  
7. ( TITLE-ABS-
KEY ( ( wound*  W/5  ( heal*  OR  infect*  OR  management  OR  care  OR  complication*  
OR  swell*  OR  clean*  OR  dressing*  OR  stitch*  OR  suture*  OR  bandage* ) ) ) )  OR  ( ( 
TITLE-ABS-
KEY ( antibiotic*  OR  antimicrobial*  OR  antibacterial*  OR  penicillin*  OR  cephalospori
n*  OR  aminoglycoside*  OR  quinolone*  OR  clindamycin  OR  metronidazole  OR  trimet
hoprim  OR  mupirocin  OR  "pseudomonic acid"  OR  neomycin  OR  "fusidic 
acid"  OR  framycetin )  OR  TITLE-ABS-
KEY ( polymyxin*  OR  chlortetracycline ) ) )  OR  ( ( TITLE-ABS-
KEY ( antiseptic*  OR  soap*  OR  iodophor*  OR  povidone  OR  iodine  OR  chlorhexidine 
 OR  betadine  OR  alcohol*  OR  disinfectant*  OR  "hydrogen peroxide"  OR  "benzoyl 
peroxide"  OR  "gentian violet"  OR  hypochlorit* )  OR  TITLE-ABS-
KEY ( eusol  OR  dakin*  OR  hexachlorophene  OR  benzalkonium  OR  "potassium 
permanganate"  OR  silver  OR  "silver sulphadiazine"  OR  honey* ) ) ) 
8. ( ( TITLE-ABS-KEY ( ( auditory  W/5  ( implant*  OR  prosthe* ) ) ) )  OR  ( TITLE-ABS-
KEY ( ( "Advance bionics"  OR  cochlea*  OR  oticon  OR  med-el ) ) ) )  AND  ( ( TITLE-
ABS-
KEY ( ( wound*  W/5  ( heal*  OR  infect*  OR  management  OR  care  OR  complication*  
OR  swell*  OR  clean*  OR  dressing*  OR  stitch*  OR  suture*  OR  bandage* ) ) ) )  OR  ( ( 
TITLE-ABS-
KEY ( antibiotic*  OR  antimicrobial*  OR  antibacterial*  OR  penicillin*  OR  cephalospori
n*  OR  aminoglycoside*  OR  quinolone*  OR  clindamycin  OR  metronidazole  OR  trimet
hoprim  OR  mupirocin  OR  "pseudomonic acid"  OR  neomycin  OR  "fusidic 
acid"  OR  framycetin )  OR  TITLE-ABS-
KEY ( polymyxin*  OR  chlortetracycline ) ) )  OR  ( ( TITLE-ABS-
KEY ( antiseptic*  OR  soap*  OR  iodophor*  OR  povidone  OR  iodine  OR  chlorhexidine 
 OR  betadine  OR  alcohol*  OR  disinfectant*  OR  "hydrogen peroxide"  OR  "benzoyl 
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KEY ( eusol  OR  dakin*  OR  hexachlorophene  OR  benzalkonium  OR  "potassium 
































Summary of results Evidence 
level 
P Hirsch et 
al.  
2007 Retrospective 
case  series  
95 3 (0) Cefazolin as a single dose 30 min before skin 
incision. No major and 3 minor infections 
4 
P Clark et al. 1980 Expert opinion N/A N/A Authors described their own experience of 
various pre-operative, intraoperative and post-




et al.  
2004 Retrospective 
case series 
292 12 (2) Higher  infection rate with C incision, extended 




2018 Case-control 188 0 (0) No difference between single shot prophylaxis, 




et al.  
2009 Cohort study 196 9 (9) Surgical site risk infection rate was 8.1 times higher 
in patients treated only with ceftriaxone and classical 
postoperative prophylaxis compared to those also 
2b 
given clarithromycin.  
P + 
M 
Gluth et al. 
 
2011 Expert opinion n/a N/A Authors discuss their expert opinion on methods 
to prevent and manage cochlear implant 
infections including dealing with chronic otitis 
media first before implantation. 
 
5 




360 4 (2) Pseudomonas spp. infections are difficult to treat and 
may require earlier explantation.. 
4 




452 2 (2) There were five major complications: two soft tissue 
infections, one extrusion, and two major seromas 
leading to device migration. Four of them involved 
loss of device fixation. Three required device 
explantation  
4 




1076 0 (0) Revision surgery with resection of infected tissue, 
formation of a rotational two- layer flap preceded and 
supplemented by intensive targeted antibiotic therapy 
should be the first treatment option. 
4 
M Low et al. 2013 Retrospective 432 8 (2) Polyprolene and radiotherapy were quoted risk 4 
case series factors for wound infections. Suggested management 
included 6 weeks of intravenous antibiotics, 
aggressive washouts and transposition of device if 
necessary.  
M Olsen et al. 2018 Retrospective 
case series 
653 11 (8) The major and minor infection rates were 2% and 
8%, respectively. The explantation rate due to 
infection was 1%. The most common pathogen found 
was Staphylococcus aureus and biofilm formation 
was found in 73% of the explantations.    
4 




350 11 (3) In the surgical wound infection group the bacteria 
isolated were Staphylococcus spp. 6 out of 7 wound 
infections were successfully treated with oral 






4 4 (0) 4 patients required surgery for infectious flap related 
issues where the implant was trans positioned and 




Table 1. Summary of articles 
included in systematic review 
alongside level of evidence. 









M Rubin et 
al.  
2010 Expert opinion 
/ policy 
statement 
N/A N/A Authors describe their experience and evidence 
within the literature on how to manage various 
cochlear implantation complications.   
5 
 
Records identified through 
database searching 


































Additional records identified 
through other sources 
(n = 0) 
Records after duplicates removed 
(n = 9267) 
Record titles screened 
(n = 9267) 
Records titles excluded 
(n = 9223) 
Abstracts assessed for 
eligibility 
(n = 44) 
Abstracts excluded 
(n = 12) 
Full text articles reviewed 
(n = 32) 
Final studies included  
(n =14) 
Further articles excluded  
       (n = 18) 
- Non-English articles (1) 
- Case report (1) 
- Conference abtracts (5) 
- Articles focusing purely on 
incidence reporting (7) 
- Article not relevant to 
wound infection (2) 
- Full-text unavailable (2) 
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